+357 96 030922
info@marketpublishers.com

Global Gastrointestinal Drugs Supply, Demand and Key Producers, 2026-2032

https://marketpublishers.com/r/GFE2DD8B2B5FEN.html
Date: September 2026
Pages: 159
Price: US$ 4,480.00 (Single User License)
ID: GFE2DD8B2B5FEN

Abstracts

The global Gastrointestinal Drugs market size is expected to reach $ 122234 million by 2032, rising at a market growth of 5.0% CAGR during the forecast period (2026-2032).

Gastrointestinal Drugs refer to pharmaceutical products used for the prevention, symptom control, disease modification, and long-term management of disorders affecting the stomach, intestine, and related digestive functions. The market spans acid-related disorder drugs, inflammatory bowel disease drugs, irritable bowel syndrome drugs, constipation drugs, diarrhea drugs, gastrointestinal motility disorder drugs, and other gastrointestinal therapies. From a pharmacological perspective, the study covers acid suppressants, gastrointestinal anti-inflammatory drugs, immunomodulators and targeted therapies, gastrointestinal motility modulators, laxatives and intestinal secretagogues, antidiarrheal and intestinal anti-infective drugs, gastrointestinal mucosal protective drugs, and other mechanisms. Product forms include oral solid preparations, oral liquids and suspensions, injectable preparations, rectal preparations, and other formulations, while molecular modalities are divided into small molecule drugs and biologic drugs. The principal downstream channels covered by the study are hospitals, gastroenterology clinics, retail pharmacies, and online pharmacies, reflecting the combination of specialist-managed prescription treatment and long-term outpatient medication characteristic of the Gastrointestinal Drugs market.

Key Findings

Targeted biologics are reshaping advanced inflammatory bowel disease treatment

+357 96 030922
info@marketpublishers.com

PCABs broaden mechanism choice in acid-related gastrointestinal therapy

Oral solid formulations remain central across chronic gastrointestinal treatment

Specialist channels anchor adoption of advanced gastrointestinal therapies

Small molecules and biologics create a dual-modality market structure

Market Trends

The Gastrointestinal Drugs market is evolving from broad symptom management toward more mechanism-specific, disease-modifying and patient-convenient therapies. In inflammatory bowel disease, therapeutic innovation has expanded beyond conventional anti-inflammatory and immunosuppressive approaches toward selective cytokine-targeted biologics and advanced oral therapies. Recent approvals involving IL-23 inhibitors and oral S1P-modulating therapies illustrate this diversification, while subcutaneous maintenance formulations are reducing dependence on infusion-based administration for some biologic treatments. In acid-related disorders, potassium-competitive acid blockers are adding a differentiated mechanism alongside established proton pump inhibition. Functional gastrointestinal disorders are also seeing continued innovation through intestinal secretagogues and locally acting or gut-focused small molecules. Together, these changes indicate that future competition will increasingly depend on mechanism differentiation, depth of clinical response, administration convenience, broader indication coverage, and the ability to support chronic treatment outside traditional hospital settings.

Market Dynamics

Drivers

Demand for Gastrointestinal Drugs is supported by the chronic and recurrent nature of many gastrointestinal conditions and by the continuing need to improve symptom control, mucosal healing, disease remission, and quality of life. More importantly, pharmaceutical innovation is expanding the treatable population by offering additional mechanisms for patients who respond inadequately to established therapies. The availability of targeted biologics, novel oral agents, newer acid-suppression

+357 96 030922
info@marketpublishers.com

mechanisms, and differentiated treatments for constipation and irritable bowel syndrome is increasing therapeutic choice and encouraging more individualized treatment pathways. Product lifecycle expansion through additional indications, age groups, and administration formats also supports sustained demand beyond initial product launch.

Restraints

The market is constrained by substantial differences in commercial economics between mature gastrointestinal medicines and innovative therapies. Established acid suppressants, motility agents, laxatives, and other long-standing small molecules are exposed to generic competition and price pressure, limiting differentiation based solely on formulation or mechanism. At the other end of the market, biologics and advanced targeted therapies require significant clinical-development investment, complex manufacturing and pharmacovigilance systems, and often face reimbursement and access restrictions. Safety monitoring requirements and treatment-selection complexity can further slow uptake of advanced agents, while the availability of multiple therapeutic alternatives increases the evidence required to demonstrate clinically meaningful differentiation.

Opportunities

The most attractive opportunities are shifting toward areas where existing treatment pathways still leave meaningful unmet need. In inflammatory bowel disease, opportunities remain in achieving deeper and more durable responses, expanding convenient subcutaneous or oral treatment options, and extending differentiated therapies across ulcerative colitis and Crohn’s disease. In acid-related disorders, newer mechanisms create room to address patients whose symptoms are not adequately controlled by established approaches. Functional bowel disorders provide another opportunity for mechanism-based oral therapies targeting constipation, diarrhea, secretion, motility, or intestinal transport. Lifecycle management through new indications, new age groups, optimized dosing, and more convenient formulations is also becoming an increasingly important source of product value.

Challenges

The principal challenge is maintaining clear clinical and commercial differentiation as

+357 96 030922
info@marketpublishers.com

the number of treatment mechanisms increases. This is especially relevant in inflammatory bowel disease, where biologics and advanced small molecules increasingly compete for overlapping patient populations and treatment lines. Manufacturers must demonstrate not only efficacy but also durability of response, acceptable safety, convenient administration, and practical advantages within real-world treatment pathways. For mature gastrointestinal categories, commoditization and generic substitution remain persistent pressures. Differences in reimbursement, prescribing practices, regulatory requirements, and access between countries also make global commercialization uneven, increasing the importance of region-specific evidence and market-access strategies.

Industry Chain Analysis

The Gastrointestinal Drugs industry chain begins with active pharmaceutical ingredients, biologic drug substances, excipients, formulation materials, delivery-device components where applicable, and pharmaceutical packaging. Midstream activities encompass drug discovery, preclinical and clinical development, formulation development, regulatory registration, API and finished-dose manufacturing, biologic production, fill-finish, quality control, and commercialization. The technical and capital intensity of this chain varies substantially by product type: conventional oral small molecules rely heavily on efficient synthesis, formulation, scale manufacturing and cost control, while targeted biologics require cell-culture or other biological production systems, more complex analytical control, cold-chain capabilities in many cases, and higher manufacturing-quality requirements.

Downstream value is realized through hospitals, gastroenterology clinics, retail pharmacies, and online pharmacies. Specialist medical institutions play the most important role in diagnosis, treatment initiation and monitoring of severe or complex diseases, particularly inflammatory bowel disease, while retail and online channels are increasingly relevant to repeat dispensing of chronic oral therapies. Across the chain, value creation is progressively shifting from simple drug availability toward therapeutic differentiation, clinical evidence, formulation convenience, reliable manufacturing, patient adherence support and market access. The resulting profitability structure therefore differs markedly between mature genericized gastrointestinal drugs and patent-protected, differentiated specialty therapies.

Segment Insights

+357 96 030922
info@marketpublishers.com

By therapeutic area, the Gastrointestinal Drugs market contains both mature high-volume categories and innovation-intensive specialty segments. Acid-related disorder drugs have a broad clinical base and a well-established treatment pathway, but new acid-suppression mechanisms are creating additional differentiation within this mature field. Inflammatory bowel disease represents one of the most innovation-intensive segments because treatment is moving toward targeted biologics and advanced small molecules addressing specific immune pathways. Irritable bowel syndrome, constipation, diarrhea and gastrointestinal motility disorders remain predominantly oral-treatment markets, where differentiation increasingly depends on mechanism, symptom coverage, tolerability and treatment convenience.

From a dosage-form perspective, oral solid preparations retain the broadest applicability because they serve both common gastrointestinal conditions and an increasing number of specialty indications. Injectable preparations remain strategically important in biologic therapy, particularly for inflammatory bowel disease, although development of subcutaneous maintenance and self-administration options is gradually changing treatment delivery. From a molecular perspective, small molecule drugs continue to support broad outpatient use and mechanism diversity, while biologic drugs provide highly targeted approaches in immune-mediated gastrointestinal diseases. The coexistence of the two modalities is creating a market in which convenience and therapeutic specificity increasingly compete alongside traditional efficacy and safety considerations.

Downstream Market Opportunities

Hospitals and gastroenterology clinics remain central to the initiation and management of advanced Gastrointestinal Drugs because diagnosis, disease-severity assessment, biologic initiation, treatment switching and safety monitoring require specialist involvement. Retail pharmacies and online pharmacies are more relevant to recurring outpatient prescriptions, particularly oral acid suppressants, gastrointestinal motility drugs, constipation therapies and other chronic medications. The expansion of once-daily oral advanced treatments and subcutaneous self-administered formulations is gradually broadening the role of outpatient and home-based treatment, creating opportunities for products that reduce administration burden while maintaining long-term disease control.

Regional Insights

+357 96 030922
info@marketpublishers.com

Regional development of the Gastrointestinal Drugs market is increasingly differentiated by regulatory access, reimbursement systems, specialist treatment infrastructure, and the speed at which novel mechanisms enter clinical practice. North America is an important launch and commercialization market for innovative gastrointestinal therapies, with recent regulatory activity spanning PCAB acid suppression, IL-23 biologics, oral advanced ulcerative colitis therapies, and expanded treatments for functional gastrointestinal disorders. Europe similarly supports adoption of advanced therapies but places greater emphasis on country-specific reimbursement and health-technology assessment, resulting in varying commercialization timelines after regulatory approval.

Asia represents a structurally important market for both established gastrointestinal medicines and newer mechanisms. Japan has been an early commercial market for potassium-competitive acid blockers, while China combines a large conventional gastrointestinal drug base with expanding demand for higher-value specialty treatment. Regional opportunity therefore does not depend on a single product category: mature markets are increasingly driven by therapeutic replacement and innovation, while developing markets retain additional potential from improving diagnosis, specialist treatment penetration, pharmaceutical access, and availability of differentiated therapies.

Report Scope

This report studies the global Gastrointestinal Drugs demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Gastrointestinal Drugs, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Gastrointestinal Drugs that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Gastrointestinal Drugs total market, 2021-2032, (USD Million)

Global Gastrointestinal Drugs total market by region & country, CAGR, 2021-2032, (USD Million)

+357 96 030922
info@marketpublishers.com

U.S. VS China: Gastrointestinal Drugs total market, key domestic companies, and share, (USD Million)

Global Gastrointestinal Drugs revenue by player, revenue and market share 2021-2026, (USD Million)

Global Gastrointestinal Drugs total market by Type, CAGR, 2021-2032, (USD Million)

Global Gastrointestinal Drugs total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Gastrointestinal Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, Sanofi, Bayer, Pfizer, GlaxoSmithKline, Teva, Ferring Pharmaceuticals, Perrigo, Boehringer Ingelheim, Purdue Pharma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Gastrointestinal Drugs market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Gastrointestinal Drugs Market, By Region:

United States

+357 96 030922
info@marketpublishers.com

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Market Segmentation

Global Gastrointestinal Drugs Market, Segmentation by Type:

Acid-Related Disorder Drugs

Inflammatory Bowel Disease Drugs

Irritable Bowel Syndrome Drugs

Constipation Drugs

Diarrhea Drugs

Gastrointestinal Motility Disorder Drugs

Other Gastrointestinal Drugs

Global Gastrointestinal Drugs Market, Segmentation by Primary Dosage:

Oral Solid Preparations

+357 96 030922
info@marketpublishers.com

Oral Liquid and Suspension Preparations

Injectable Preparations

Rectal Preparations

Other Preparations

Global Gastrointestinal Drugs Market, Segmentation by Drug Molecule:

Small Molecule Drugs

Biologic Drugs

Global Gastrointestinal Drugs Market, Segmentation by Application:

Inflammatory Bowel Disease

IBS Disease

Peptic Ulcer

GERD

Other

Companies Profiled:

AstraZeneca

Sanofi

Bayer

+357 96 030922
info@marketpublishers.com

Pfizer

GlaxoSmithKline

Teva

Ferring Pharmaceuticals

Perrigo

Boehringer Ingelheim

Purdue Pharma

Dr. Falk Pharma GmbH

Abbott

Jiangzhong

Xian-Janssen

Takeda Pharmaceutical

AbbVie

Eli Lilly and Company

Johnson & Johnson

Bristol Myers Squibb

Bausch Health

Livzon Pharmaceutical

Shandong Luoxin Pharmaceutical

+357 96 030922
info@marketpublishers.com

Gilead Sciences

Zhengdatianqing

Zydus Lifesciences

Key Questions Answered

1. How big is the global Gastrointestinal Drugs market?
2. What is the demand of the global Gastrointestinal Drugs market?
3. What is the year over year growth of the global Gastrointestinal Drugs market?
4. What is the total value of the global Gastrointestinal Drugs market?
5. Who are the Major Players in the global Gastrointestinal Drugs market?
6. What are the growth factors driving the market demand?

+357 96 030922
info@marketpublishers.com

Contents

1 SUPPLY SUMMARY

1.1 Gastrointestinal Drugs Introduction
1.2 World Gastrointestinal Drugs Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Gastrointestinal Drugs Total Market by Region (by Headquarter Location)
  1.3.1 World Gastrointestinal Drugs Market Size by Region (2021-2032), (by Headquarter Location)
  1.3.2 United States Based Company Gastrointestinal Drugs Revenue (2021-2032)
  1.3.3 China Based Company Gastrointestinal Drugs Revenue (2021-2032)
  1.3.4 Europe Based Company Gastrointestinal Drugs Revenue (2021-2032)
  1.3.5 Japan Based Company Gastrointestinal Drugs Revenue (2021-2032)
  1.3.6 South Korea Based Company Gastrointestinal Drugs Revenue (2021-2032)
  1.3.7 ASEAN Based Company Gastrointestinal Drugs Revenue (2021-2032)
  1.3.8 India Based Company Gastrointestinal Drugs Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Gastrointestinal Drugs Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Major Market Trends

2 DEMAND SUMMARY

2.1 World Gastrointestinal Drugs Consumption Value (2021-2032)
2.2 World Gastrointestinal Drugs Consumption Value by Region
  2.2.1 World Gastrointestinal Drugs Consumption Value by Region (2021-2026)
  2.2.2 World Gastrointestinal Drugs Consumption Value Forecast by Region (2027-2032)
2.3 United States Gastrointestinal Drugs Consumption Value (2021-2032)
2.4 China Gastrointestinal Drugs Consumption Value (2021-2032)
2.5 Europe Gastrointestinal Drugs Consumption Value (2021-2032)
2.6 Japan Gastrointestinal Drugs Consumption Value (2021-2032)
2.7 South Korea Gastrointestinal Drugs Consumption Value (2021-2032)
2.8 ASEAN Gastrointestinal Drugs Consumption Value (2021-2032)
2.9 India Gastrointestinal Drugs Consumption Value (2021-2032)

3 WORLD GASTROINTESTINAL DRUGS COMPANIES COMPETITIVE ANALYSIS

3.1 World Gastrointestinal Drugs Revenue by Player (2021-2026)

+357 96 030922
info@marketpublishers.com

3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Gastrointestinal Drugs Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Gastrointestinal Drugs in 2025
3.2.3 Global Concentration Ratios (CR8) for Gastrointestinal Drugs in 2025
3.3 Gastrointestinal Drugs Company Evaluation Quadrant
3.4 Gastrointestinal Drugs Market: Overall Company Footprint Analysis
3.4.1 Gastrointestinal Drugs Market: Region Footprint
3.4.2 Gastrointestinal Drugs Market: Company Product Type Footprint
3.4.3 Gastrointestinal Drugs Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: Gastrointestinal Drugs Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Gastrointestinal Drugs Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Gastrointestinal Drugs Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Gastrointestinal Drugs Consumption Value Comparison
4.2.1 United States VS China: Gastrointestinal Drugs Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Gastrointestinal Drugs Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Gastrointestinal Drugs Companies and Market Share, 2021-2026
4.3.1 United States Based Gastrointestinal Drugs Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Gastrointestinal Drugs Revenue, (2021-2026)
4.4 China Based Companies Gastrointestinal Drugs Revenue and Market Share, 2021-2026
4.4.1 China Based Gastrointestinal Drugs Companies, Company Headquarters (Province, Country)

+357 96 030922
info@marketpublishers.com

4.4.2 China Based Companies Gastrointestinal Drugs Revenue, (2021-2026)
4.5 Rest of World Based Gastrointestinal Drugs Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Gastrointestinal Drugs Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Gastrointestinal Drugs Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Gastrointestinal Drugs Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Acid-Related Disorder Drugs
5.2.2 Inflammatory Bowel Disease Drugs
5.2.3 Irritable Bowel Syndrome Drugs
5.2.4 Constipation Drugs
5.2.5 Diarrhea Drugs
5.2.6 Gastrointestinal Motility Disorder Drugs
5.2.7 Other Gastrointestinal Drugs
5.3 Market Segment by Type
5.3.1 World Gastrointestinal Drugs Market Size by Type (2021-2026)
5.3.2 World Gastrointestinal Drugs Market Size by Type (2027-2032)
5.3.3 World Gastrointestinal Drugs Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY PRIMARY DOSAGE

6.1 World Gastrointestinal Drugs Market Size Overview by Primary Dosage: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Primary Dosage
6.2.1 Oral Solid Preparations
6.2.2 Oral Liquid and Suspension Preparations
6.2.3 Injectable Preparations
6.2.4 Rectal Preparations
6.2.5 Other Preparations
6.3 Market Segment by Primary Dosage
6.3.1 World Gastrointestinal Drugs Market Size by Primary Dosage (2021-2026)
6.3.2 World Gastrointestinal Drugs Market Size by Primary Dosage (2027-2032)
6.3.3 World Gastrointestinal Drugs Market Size Market Share by Primary Dosage (2027-2032)

+357 96 030922
info@marketpublishers.com

7 MARKET ANALYSIS BY DRUG MOLECULE

7.1 World Gastrointestinal Drugs Market Size Overview by Drug Molecule: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Drug Molecule
  7.2.1 Small Molecule Drugs
  7.2.2 Biologic Drugs
7.3 Market Segment by Drug Molecule
  7.3.1 World Gastrointestinal Drugs Market Size by Drug Molecule (2021-2026)
  7.3.2 World Gastrointestinal Drugs Market Size by Drug Molecule (2027-2032)
  7.3.3 World Gastrointestinal Drugs Market Size Market Share by Drug Molecule (2027-2032)

8 MARKET ANALYSIS BY APPLICATION

8.1 World Gastrointestinal Drugs Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
  8.2.1 Inflammatory Bowel Disease
  8.2.2 IBS Disease
  8.2.3 Peptic Ulcer
  8.2.4 GERD
  8.2.5 Other
8.3 Market Segment by Application
  8.3.1 World Gastrointestinal Drugs Market Size by Application (2021-2026)
  8.3.2 World Gastrointestinal Drugs Market Size by Application (2027-2032)
  8.3.3 World Gastrointestinal Drugs Market Size Market Share by Application (2021-2032)

9 COMPANY PROFILES

9.1 AstraZeneca
  9.1.1 AstraZeneca Details
  9.1.2 AstraZeneca Major Business
  9.1.3 AstraZeneca Gastrointestinal Drugs Product and Services
  9.1.4 AstraZeneca Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
  9.1.5 AstraZeneca Recent Developments/Updates

+357 96 030922
info@marketpublishers.com

9.1.6 AstraZeneca Competitive Strengths & Weaknesses
9.2 Sanofi
9.2.1 Sanofi Details
9.2.2 Sanofi Major Business
9.2.3 Sanofi Gastrointestinal Drugs Product and Services
9.2.4 Sanofi Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Sanofi Recent Developments/Updates
9.2.6 Sanofi Competitive Strengths & Weaknesses
9.3 Bayer
9.3.1 Bayer Details
9.3.2 Bayer Major Business
9.3.3 Bayer Gastrointestinal Drugs Product and Services
9.3.4 Bayer Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Bayer Recent Developments/Updates
9.3.6 Bayer Competitive Strengths & Weaknesses
9.4 Pfizer
9.4.1 Pfizer Details
9.4.2 Pfizer Major Business
9.4.3 Pfizer Gastrointestinal Drugs Product and Services
9.4.4 Pfizer Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Pfizer Recent Developments/Updates
9.4.6 Pfizer Competitive Strengths & Weaknesses
9.5 GlaxoSmithKline
9.5.1 GlaxoSmithKline Details
9.5.2 GlaxoSmithKline Major Business
9.5.3 GlaxoSmithKline Gastrointestinal Drugs Product and Services
9.5.4 GlaxoSmithKline Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 GlaxoSmithKline Recent Developments/Updates
9.5.6 GlaxoSmithKline Competitive Strengths & Weaknesses
9.6 Teva
9.6.1 Teva Details
9.6.2 Teva Major Business
9.6.3 Teva Gastrointestinal Drugs Product and Services
9.6.4 Teva Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)

+357 96 030922
info@marketpublishers.com

9.6.5 Teva Recent Developments/Updates
9.6.6 Teva Competitive Strengths & Weaknesses
9.7 Ferring Pharmaceuticals
9.7.1 Ferring Pharmaceuticals Details
9.7.2 Ferring Pharmaceuticals Major Business
9.7.3 Ferring Pharmaceuticals Gastrointestinal Drugs Product and Services
9.7.4 Ferring Pharmaceuticals Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Ferring Pharmaceuticals Recent Developments/Updates
9.7.6 Ferring Pharmaceuticals Competitive Strengths & Weaknesses
9.8 Perrigo
9.8.1 Perrigo Details
9.8.2 Perrigo Major Business
9.8.3 Perrigo Gastrointestinal Drugs Product and Services
9.8.4 Perrigo Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Perrigo Recent Developments/Updates
9.8.6 Perrigo Competitive Strengths & Weaknesses
9.9 Boehringer Ingelheim
9.9.1 Boehringer Ingelheim Details
9.9.2 Boehringer Ingelheim Major Business
9.9.3 Boehringer Ingelheim Gastrointestinal Drugs Product and Services
9.9.4 Boehringer Ingelheim Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Boehringer Ingelheim Recent Developments/Updates
9.9.6 Boehringer Ingelheim Competitive Strengths & Weaknesses
9.10 Purdue Pharma
9.10.1 Purdue Pharma Details
9.10.2 Purdue Pharma Major Business
9.10.3 Purdue Pharma Gastrointestinal Drugs Product and Services
9.10.4 Purdue Pharma Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Purdue Pharma Recent Developments/Updates
9.10.6 Purdue Pharma Competitive Strengths & Weaknesses
9.11 Dr. Falk Pharma GmbH
9.11.1 Dr. Falk Pharma GmbH Details
9.11.2 Dr. Falk Pharma GmbH Major Business
9.11.3 Dr. Falk Pharma GmbH Gastrointestinal Drugs Product and Services
9.11.4 Dr. Falk Pharma GmbH Gastrointestinal Drugs Revenue, Gross Margin and

+357 96 030922
info@marketpublishers.com

Market Share (2021-2026)
9.11.5 Dr. Falk Pharma GmbH Recent Developments/Updates
9.11.6 Dr. Falk Pharma GmbH Competitive Strengths & Weaknesses
9.12 Abbott
9.12.1 Abbott Details
9.12.2 Abbott Major Business
9.12.3 Abbott Gastrointestinal Drugs Product and Services
9.12.4 Abbott Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Abbott Recent Developments/Updates
9.12.6 Abbott Competitive Strengths & Weaknesses
9.13 Jiangzhong
9.13.1 Jiangzhong Details
9.13.2 Jiangzhong Major Business
9.13.3 Jiangzhong Gastrointestinal Drugs Product and Services
9.13.4 Jiangzhong Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Jiangzhong Recent Developments/Updates
9.13.6 Jiangzhong Competitive Strengths & Weaknesses
9.14 Xian-Janssen
9.14.1 Xian-Janssen Details
9.14.2 Xian-Janssen Major Business
9.14.3 Xian-Janssen Gastrointestinal Drugs Product and Services
9.14.4 Xian-Janssen Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Xian-Janssen Recent Developments/Updates
9.14.6 Xian-Janssen Competitive Strengths & Weaknesses
9.15 Takeda Pharmaceutical
9.15.1 Takeda Pharmaceutical Details
9.15.2 Takeda Pharmaceutical Major Business
9.15.3 Takeda Pharmaceutical Gastrointestinal Drugs Product and Services
9.15.4 Takeda Pharmaceutical Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 Takeda Pharmaceutical Recent Developments/Updates
9.15.6 Takeda Pharmaceutical Competitive Strengths & Weaknesses
9.16 AbbVie
9.16.1 AbbVie Details
9.16.2 AbbVie Major Business
9.16.3 AbbVie Gastrointestinal Drugs Product and Services

+357 96 030922
info@marketpublishers.com

9.16.4 AbbVie Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 AbbVie Recent Developments/Updates
9.16.6 AbbVie Competitive Strengths & Weaknesses
9.17 Eli Lilly and Company
9.17.1 Eli Lilly and Company Details
9.17.2 Eli Lilly and Company Major Business
9.17.3 Eli Lilly and Company Gastrointestinal Drugs Product and Services
9.17.4 Eli Lilly and Company Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 Eli Lilly and Company Recent Developments/Updates
9.17.6 Eli Lilly and Company Competitive Strengths & Weaknesses
9.18 Johnson & Johnson
9.18.1 Johnson & Johnson Details
9.18.2 Johnson & Johnson Major Business
9.18.3 Johnson & Johnson Gastrointestinal Drugs Product and Services
9.18.4 Johnson & Johnson Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Johnson & Johnson Recent Developments/Updates
9.18.6 Johnson & Johnson Competitive Strengths & Weaknesses
9.19 Bristol Myers Squibb
9.19.1 Bristol Myers Squibb Details
9.19.2 Bristol Myers Squibb Major Business
9.19.3 Bristol Myers Squibb Gastrointestinal Drugs Product and Services
9.19.4 Bristol Myers Squibb Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 Bristol Myers Squibb Recent Developments/Updates
9.19.6 Bristol Myers Squibb Competitive Strengths & Weaknesses
9.20 Bausch Health
9.20.1 Bausch Health Details
9.20.2 Bausch Health Major Business
9.20.3 Bausch Health Gastrointestinal Drugs Product and Services
9.20.4 Bausch Health Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 Bausch Health Recent Developments/Updates
9.20.6 Bausch Health Competitive Strengths & Weaknesses
9.21 Livzon Pharmaceutical
9.21.1 Livzon Pharmaceutical Details
9.21.2 Livzon Pharmaceutical Major Business

+357 96 030922
info@marketpublishers.com

9.21.3 Livzon Pharmaceutical Gastrointestinal Drugs Product and Services
9.21.4 Livzon Pharmaceutical Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 Livzon Pharmaceutical Recent Developments/Updates
9.21.6 Livzon Pharmaceutical Competitive Strengths & Weaknesses
9.22 Shandong Luoxin Pharmaceutical
9.22.1 Shandong Luoxin Pharmaceutical Details
9.22.2 Shandong Luoxin Pharmaceutical Major Business
9.22.3 Shandong Luoxin Pharmaceutical Gastrointestinal Drugs Product and Services
9.22.4 Shandong Luoxin Pharmaceutical Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.22.5 Shandong Luoxin Pharmaceutical Recent Developments/Updates
9.22.6 Shandong Luoxin Pharmaceutical Competitive Strengths & Weaknesses
9.23 Gilead Sciences
9.23.1 Gilead Sciences Details
9.23.2 Gilead Sciences Major Business
9.23.3 Gilead Sciences Gastrointestinal Drugs Product and Services
9.23.4 Gilead Sciences Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.23.5 Gilead Sciences Recent Developments/Updates
9.23.6 Gilead Sciences Competitive Strengths & Weaknesses
9.24 Zhengdatianqing
9.24.1 Zhengdatianqing Details
9.24.2 Zhengdatianqing Major Business
9.24.3 Zhengdatianqing Gastrointestinal Drugs Product and Services
9.24.4 Zhengdatianqing Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.24.5 Zhengdatianqing Recent Developments/Updates
9.24.6 Zhengdatianqing Competitive Strengths & Weaknesses
9.25 Zydus Lifesciences
9.25.1 Zydus Lifesciences Details
9.25.2 Zydus Lifesciences Major Business
9.25.3 Zydus Lifesciences Gastrointestinal Drugs Product and Services
9.25.4 Zydus Lifesciences Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
9.25.5 Zydus Lifesciences Recent Developments/Updates
9.25.6 Zydus Lifesciences Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

+357 96 030922
info@marketpublishers.com

10.1 Gastrointestinal Drugs Industry Chain
10.2 Gastrointestinal Drugs Upstream Analysis
10.3 Gastrointestinal Drugs Midstream Analysis
10.4 Gastrointestinal Drugs Downstream Analysis

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. World Gastrointestinal Drugs Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Gastrointestinal Drugs Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Gastrointestinal Drugs Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Gastrointestinal Drugs Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Gastrointestinal Drugs Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Gastrointestinal Drugs Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Gastrointestinal Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Gastrointestinal Drugs Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Gastrointestinal Drugs Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Gastrointestinal Drugs Players in 2025
Table 12. World Gastrointestinal Drugs Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Gastrointestinal Drugs Company Evaluation Quadrant
Table 14. Head Office of Key Gastrointestinal Drugs Players
Table 15. Gastrointestinal Drugs Market: Company Product Type Footprint
Table 16. Gastrointestinal Drugs Market: Company Product Application Footprint
Table 17. Gastrointestinal Drugs Mergers & Acquisitions Activity
Table 18. United States VS China Gastrointestinal Drugs Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Gastrointestinal Drugs Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Gastrointestinal Drugs Companies, Headquarters (States, Country)
Table 21. United States Based Companies Gastrointestinal Drugs Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Gastrointestinal Drugs Revenue Market

+357 96 030922
info@marketpublishers.com

Share (2021-2026)
Table 23. China Based Gastrointestinal Drugs Companies, Headquarters (Province, Country)
Table 24. China Based Companies Gastrointestinal Drugs Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Gastrointestinal Drugs Revenue Market Share (2021-2026)
Table 26. Rest of World Based Gastrointestinal Drugs Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Gastrointestinal Drugs Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Gastrointestinal Drugs Revenue Market Share (2021-2026)
Table 29. World Gastrointestinal Drugs Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Gastrointestinal Drugs Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Gastrointestinal Drugs Market Size by Type (2027-2032) & (USD Million)
Table 32. World Gastrointestinal Drugs Market Size by Primary Dosage, (USD Million), 2021 & 2025 & 2032
Table 33. World Gastrointestinal Drugs Market Size Value by Primary Dosage (2021-2026) & (USD Million)
Table 34. World Gastrointestinal Drugs Market Size by Primary Dosage (2027-2032) & (USD Million)
Table 35. World Gastrointestinal Drugs Market Size by Drug Molecule, (USD Million), 2021 & 2025 & 2032
Table 36. World Gastrointestinal Drugs Market Size Value by Drug Molecule (2021-2026) & (USD Million)
Table 37. World Gastrointestinal Drugs Market Size by Drug Molecule (2027-2032) & (USD Million)
Table 38. World Gastrointestinal Drugs Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Gastrointestinal Drugs Market Size by Application (2021-2026) & (USD Million)
Table 40. World Gastrointestinal Drugs Market Size by Application (2027-2032) & (USD Million)
Table 41. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 42. AstraZeneca Major Business

+357 96 030922
info@marketpublishers.com

Table 43. AstraZeneca Gastrointestinal Drugs Product and Services
Table 44. AstraZeneca Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. AstraZeneca Recent Developments/Updates
Table 46. AstraZeneca Competitive Strengths & Weaknesses
Table 47. Sanofi Basic Information, Manufacturing Base and Competitors
Table 48. Sanofi Major Business
Table 49. Sanofi Gastrointestinal Drugs Product and Services
Table 50. Sanofi Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Sanofi Recent Developments/Updates
Table 52. Sanofi Competitive Strengths & Weaknesses
Table 53. Bayer Basic Information, Manufacturing Base and Competitors
Table 54. Bayer Major Business
Table 55. Bayer Gastrointestinal Drugs Product and Services
Table 56. Bayer Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Bayer Recent Developments/Updates
Table 58. Bayer Competitive Strengths & Weaknesses
Table 59. Pfizer Basic Information, Manufacturing Base and Competitors
Table 60. Pfizer Major Business
Table 61. Pfizer Gastrointestinal Drugs Product and Services
Table 62. Pfizer Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Pfizer Recent Developments/Updates
Table 64. Pfizer Competitive Strengths & Weaknesses
Table 65. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 66. GlaxoSmithKline Major Business
Table 67. GlaxoSmithKline Gastrointestinal Drugs Product and Services
Table 68. GlaxoSmithKline Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. GlaxoSmithKline Recent Developments/Updates
Table 70. GlaxoSmithKline Competitive Strengths & Weaknesses
Table 71. Teva Basic Information, Manufacturing Base and Competitors
Table 72. Teva Major Business
Table 73. Teva Gastrointestinal Drugs Product and Services
Table 74. Teva Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Teva Recent Developments/Updates

+357 96 030922
info@marketpublishers.com

Table 76. Teva Competitive Strengths & Weaknesses
Table 77. Ferring Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 78. Ferring Pharmaceuticals Major Business
Table 79. Ferring Pharmaceuticals Gastrointestinal Drugs Product and Services
Table 80. Ferring Pharmaceuticals Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Ferring Pharmaceuticals Recent Developments/Updates
Table 82. Ferring Pharmaceuticals Competitive Strengths & Weaknesses
Table 83. Perrigo Basic Information, Manufacturing Base and Competitors
Table 84. Perrigo Major Business
Table 85. Perrigo Gastrointestinal Drugs Product and Services
Table 86. Perrigo Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Perrigo Recent Developments/Updates
Table 88. Perrigo Competitive Strengths & Weaknesses
Table 89. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 90. Boehringer Ingelheim Major Business
Table 91. Boehringer Ingelheim Gastrointestinal Drugs Product and Services
Table 92. Boehringer Ingelheim Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Boehringer Ingelheim Recent Developments/Updates
Table 94. Boehringer Ingelheim Competitive Strengths & Weaknesses
Table 95. Purdue Pharma Basic Information, Manufacturing Base and Competitors
Table 96. Purdue Pharma Major Business
Table 97. Purdue Pharma Gastrointestinal Drugs Product and Services
Table 98. Purdue Pharma Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Purdue Pharma Recent Developments/Updates
Table 100. Purdue Pharma Competitive Strengths & Weaknesses
Table 101. Dr. Falk Pharma GmbH Basic Information, Manufacturing Base and Competitors
Table 102. Dr. Falk Pharma GmbH Major Business
Table 103. Dr. Falk Pharma GmbH Gastrointestinal Drugs Product and Services
Table 104. Dr. Falk Pharma GmbH Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Dr. Falk Pharma GmbH Recent Developments/Updates
Table 106. Dr. Falk Pharma GmbH Competitive Strengths & Weaknesses

+357 96 030922
info@marketpublishers.com

Table 107. Abbott Basic Information, Manufacturing Base and Competitors
Table 108. Abbott Major Business
Table 109. Abbott Gastrointestinal Drugs Product and Services
Table 110. Abbott Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Abbott Recent Developments/Updates
Table 112. Abbott Competitive Strengths & Weaknesses
Table 113. Jiangzhong Basic Information, Manufacturing Base and Competitors
Table 114. Jiangzhong Major Business
Table 115. Jiangzhong Gastrointestinal Drugs Product and Services
Table 116. Jiangzhong Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Jiangzhong Recent Developments/Updates
Table 118. Jiangzhong Competitive Strengths & Weaknesses
Table 119. Xian-Janssen Basic Information, Manufacturing Base and Competitors
Table 120. Xian-Janssen Major Business
Table 121. Xian-Janssen Gastrointestinal Drugs Product and Services
Table 122. Xian-Janssen Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Xian-Janssen Recent Developments/Updates
Table 124. Xian-Janssen Competitive Strengths & Weaknesses
Table 125. Takeda Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 126. Takeda Pharmaceutical Major Business
Table 127. Takeda Pharmaceutical Gastrointestinal Drugs Product and Services
Table 128. Takeda Pharmaceutical Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Takeda Pharmaceutical Recent Developments/Updates
Table 130. Takeda Pharmaceutical Competitive Strengths & Weaknesses
Table 131. AbbVie Basic Information, Manufacturing Base and Competitors
Table 132. AbbVie Major Business
Table 133. AbbVie Gastrointestinal Drugs Product and Services
Table 134. AbbVie Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. AbbVie Recent Developments/Updates
Table 136. AbbVie Competitive Strengths & Weaknesses
Table 137. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 138. Eli Lilly and Company Major Business

+357 96 030922
info@marketpublishers.com

Table 139. Eli Lilly and Company Gastrointestinal Drugs Product and Services
Table 140. Eli Lilly and Company Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Eli Lilly and Company Recent Developments/Updates
Table 142. Eli Lilly and Company Competitive Strengths & Weaknesses
Table 143. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 144. Johnson & Johnson Major Business
Table 145. Johnson & Johnson Gastrointestinal Drugs Product and Services
Table 146. Johnson & Johnson Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Johnson & Johnson Recent Developments/Updates
Table 148. Johnson & Johnson Competitive Strengths & Weaknesses
Table 149. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 150. Bristol Myers Squibb Major Business
Table 151. Bristol Myers Squibb Gastrointestinal Drugs Product and Services
Table 152. Bristol Myers Squibb Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. Bristol Myers Squibb Recent Developments/Updates
Table 154. Bristol Myers Squibb Competitive Strengths & Weaknesses
Table 155. Bausch Health Basic Information, Manufacturing Base and Competitors
Table 156. Bausch Health Major Business
Table 157. Bausch Health Gastrointestinal Drugs Product and Services
Table 158. Bausch Health Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. Bausch Health Recent Developments/Updates
Table 160. Bausch Health Competitive Strengths & Weaknesses
Table 161. Livzon Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 162. Livzon Pharmaceutical Major Business
Table 163. Livzon Pharmaceutical Gastrointestinal Drugs Product and Services
Table 164. Livzon Pharmaceutical Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. Livzon Pharmaceutical Recent Developments/Updates
Table 166. Livzon Pharmaceutical Competitive Strengths & Weaknesses
Table 167. Shandong Luoxin Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 168. Shandong Luoxin Pharmaceutical Major Business
Table 169. Shandong Luoxin Pharmaceutical Gastrointestinal Drugs Product and

+357 96 030922
info@marketpublishers.com

Services
Table 170. Shandong Luoxin Pharmaceutical Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 171. Shandong Luoxin Pharmaceutical Recent Developments/Updates
Table 172. Shandong Luoxin Pharmaceutical Competitive Strengths & Weaknesses
Table 173. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 174. Gilead Sciences Major Business
Table 175. Gilead Sciences Gastrointestinal Drugs Product and Services
Table 176. Gilead Sciences Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 177. Gilead Sciences Recent Developments/Updates
Table 178. Gilead Sciences Competitive Strengths & Weaknesses
Table 179. Zhengdatianqing Basic Information, Manufacturing Base and Competitors
Table 180. Zhengdatianqing Major Business
Table 181. Zhengdatianqing Gastrointestinal Drugs Product and Services
Table 182. Zhengdatianqing Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 183. Zhengdatianqing Recent Developments/Updates
Table 184. Zhengdatianqing Competitive Strengths & Weaknesses
Table 185. Zydus Lifesciences Basic Information, Manufacturing Base and Competitors
Table 186. Zydus Lifesciences Major Business
Table 187. Zydus Lifesciences Gastrointestinal Drugs Product and Services
Table 188. Zydus Lifesciences Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 189. Zydus Lifesciences Recent Developments/Updates
Table 190. Zydus Lifesciences Competitive Strengths & Weaknesses
Table 191. Global Key Players of Gastrointestinal Drugs Upstream (Raw Materials)
Table 192. Global Gastrointestinal Drugs Typical Customers

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. Gastrointestinal Drugs Picture
Figure 2. World Gastrointestinal Drugs Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Gastrointestinal Drugs Total Revenue (2021-2032) & (USD Million)
Figure 4. World Gastrointestinal Drugs Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Gastrointestinal Drugs Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Gastrointestinal Drugs Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Gastrointestinal Drugs Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Gastrointestinal Drugs Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Gastrointestinal Drugs Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Gastrointestinal Drugs Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Gastrointestinal Drugs Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Gastrointestinal Drugs Revenue (2021-2032) & (USD Million)
Figure 13. Gastrointestinal Drugs Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Gastrointestinal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 16. World Gastrointestinal Drugs Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Gastrointestinal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 18. China Gastrointestinal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Gastrointestinal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Gastrointestinal Drugs Consumption Value (2021-2032) & (USD

+357 96 030922
info@marketpublishers.com

Million)
Figure 21. South Korea Gastrointestinal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Gastrointestinal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 23. India Gastrointestinal Drugs Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Gastrointestinal Drugs by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Gastrointestinal Drugs Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Gastrointestinal Drugs Markets in 2025
Figure 27. United States VS China: Gastrointestinal Drugs Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Gastrointestinal Drugs Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Gastrointestinal Drugs Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Gastrointestinal Drugs Market Size Market Share by Type in 2025
Figure 31. Acid-Related Disorder Drugs
Figure 32. Inflammatory Bowel Disease Drugs
Figure 33. Irritable Bowel Syndrome Drugs
Figure 34. Constipation Drugs
Figure 35. Diarrhea Drugs
Figure 36. Gastrointestinal Motility Disorder Drugs
Figure 37. Other Gastrointestinal Drugs
Figure 38. Other Gastrointestinal Drugs
Figure 39. World Gastrointestinal Drugs Market Size Market Share by Type (2021-2032)
Figure 40. World Gastrointestinal Drugs Market Size by Primary Dosage, (USD Million), 2021 & 2025 & 2032
Figure 41. World Gastrointestinal Drugs Market Size Market Share by Primary Dosage in 2025
Figure 42. Oral Solid Preparations
Figure 43. Oral Liquid and Suspension Preparations
Figure 44. Injectable Preparations
Figure 45. Rectal Preparations
Figure 46. Other Preparations
Figure 47. World Gastrointestinal Drugs Market Size Market Share by Primary Dosage (2021-2032)

+357 96 030922
info@marketpublishers.com

Figure 48. World Gastrointestinal Drugs Market Size by Drug Molecule, (USD Million), 2021 & 2025 & 2032
Figure 49. World Gastrointestinal Drugs Market Size Market Share by Drug Molecule in 2025
Figure 50. Small Molecule Drugs
Figure 51. Biologic Drugs
Figure 52. World Gastrointestinal Drugs Market Size Market Share by Drug Molecule (2021-2032)
Figure 53. World Gastrointestinal Drugs Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 54. World Gastrointestinal Drugs Market Size Market Share by Application in 2025
Figure 55. Inflammatory Bowel Disease
Figure 56. IBS Disease
Figure 57. Peptic Ulcer
Figure 58. GERD
Figure 59. Other
Figure 60. World Gastrointestinal Drugs Market Size Market Share by Application (2021-2032)
Figure 61. Gastrointestinal Drugs Industrial Chain
Figure 62. Methodology
Figure 63. Research Process and Data Source

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Gastrointestinal Drugs Supply, Demand and Key Producers, 2026-2032

Product link: https://marketpublishers.com/r/GFE2DD8B2B5FEN.html

Price: US$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GFE2DD8B2B5FEN.html